Literature DB >> 9614766

The impact of influenza and influenza-like illness on productivity and healthcare resource utilization in a working population.

M Keech1, A J Scott, P J Ryan.   

Abstract

Four hundred and eleven subjects who either reported to Occupational Health at onset of influenza or influenza-like illness (I/ILI) symptoms or on return to work completed questionnaires on entry to the study and after 28 days. On average they were incapacitated or confined to bed for 2.4 days, missing 2.8 days from work per episode of illness. On return to work, they reported reduced effectiveness and inability to resume normal activity until a mean 3.5 days after the onset of symptoms. Each participant reported a mean of 6.5 I/ILI symptoms. There was a positive correlation between the number of symptoms and bed days (r = 0.24) and missed work days (r = 0.18). There was a positive correlation between the number of healthcare contact and the number of reported symptoms (r = 0.23). A relatively high level of contact with general practitioners and pharmacists was observed and there was substantial use of both prescription and over-the-counter medication. In conclusion, the impact of I/ILI on productivity in a working population and the resultant cost to employers and employees may be considerable.

Entities:  

Mesh:

Year:  1998        PMID: 9614766     DOI: 10.1093/occmed/48.2.85

Source DB:  PubMed          Journal:  Occup Med (Lond)        ISSN: 0962-7480            Impact factor:   1.611


  52 in total

Review 1.  Pharmacoeconomics of influenza vaccination for healthy working adults: reviewing the available evidence.

Authors:  Maarten J Postma; Paul Jansema; Marianne L L van Genugten; Marie-Louise A Heijnen; Johannes C Jager; Lolkje T W de Jong-van den Berg
Journal:  Drugs       Date:  2002       Impact factor: 9.546

2.  A model to estimate the cost benefit of an occupational vaccination programme for influenza with Influvac in the UK.

Authors:  Roben Das Gupta; Julian F Guest
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

3.  Influenza update: a review of currently available vaccines.

Authors:  Lisa R Clayville
Journal:  P T       Date:  2011-10

Review 4.  Antiviral agents for influenza: a comparison of cost-effectiveness data.

Authors:  Larry D Lynd; Ron Goeree; Bernie J O'Brien
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

5.  Pharmacoeconomic assessment of oseltamivir in treating influenza--the case of otherwise healthy Danish adolescents and adults.

Authors:  Majbrit Vindt Holm; Marlene Gyldmark; Ebba Holme Hansen
Journal:  Pharm World Sci       Date:  2004-12

6.  The burden of influenza-like illness in the US workforce.

Authors:  Y Tsai; F Zhou; I K Kim
Journal:  Occup Med (Lond)       Date:  2014-03-22       Impact factor: 1.611

7.  Trends of out-of-pocket expenditure for influenza in China Health and Nutrition Survey during 1989-2006.

Authors:  Jinan Liu; Lizheng Shi; Mahmud Khan; Lingzhong Xu; Liya Wang
Journal:  Int J Public Health       Date:  2011-04-19       Impact factor: 3.380

8.  Influenza vaccination coverage among high-risk groups in 11 European countries.

Authors:  Adrian Loerbroks; Christian Stock; Jos A Bosch; David G Litaker; Christian J Apfelbacher
Journal:  Eur J Public Health       Date:  2011-07-12       Impact factor: 3.367

9.  Employer-incurred health care costs and productivity losses associated with influenza.

Authors:  Sudeep Karve; Derek A Misurski; Genevieve Meier; Keith L Davis
Journal:  Hum Vaccin Immunother       Date:  2013-01-15       Impact factor: 3.452

Review 10.  The impact of influenza on working days lost: a review of the literature.

Authors:  Martin Keech; Paul Beardsworth
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.